GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (NAS:NAMS) » Definitions » EV-to-EBIT

NewAmsterdam Pharma Co NV (NewAmsterdam Pharma Co NV) EV-to-EBIT : -7.71 (As of May. 15, 2024)


View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, NewAmsterdam Pharma Co NV's Enterprise Value is $1,363.61 Mil. NewAmsterdam Pharma Co NV's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-176.91 Mil. Therefore, NewAmsterdam Pharma Co NV's EV-to-EBIT for today is -7.71.

The historical rank and industry rank for NewAmsterdam Pharma Co NV's EV-to-EBIT or its related term are showing as below:

NAMS' s EV-to-EBIT Range Over the Past 10 Years
Min: -9.06   Med: 10.17   Max: 15.24
Current: -7.73

During the past 4 years, the highest EV-to-EBIT of NewAmsterdam Pharma Co NV was 15.24. The lowest was -9.06. And the median was 10.17.

NAMS's EV-to-EBIT is ranked worse than
100% of 427 companies
in the Biotechnology industry
Industry Median: 10.05 vs NAMS: -7.73

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. NewAmsterdam Pharma Co NV's Enterprise Value for the quarter that ended in Dec. 2023 was $580.80 Mil. NewAmsterdam Pharma Co NV's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-176.91 Mil. NewAmsterdam Pharma Co NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -30.46%.

NewAmsterdam Pharma Co NV EV-to-EBIT Historical Data

The historical data trend for NewAmsterdam Pharma Co NV's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NewAmsterdam Pharma Co NV EV-to-EBIT Chart

NewAmsterdam Pharma Co NV Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - -18.86 -3.28

NewAmsterdam Pharma Co NV Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-EBIT Get a 7-Day Free Trial - - -18.86 - -3.28

Competitive Comparison of NewAmsterdam Pharma Co NV's EV-to-EBIT

For the Biotechnology subindustry, NewAmsterdam Pharma Co NV's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NewAmsterdam Pharma Co NV's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NewAmsterdam Pharma Co NV's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where NewAmsterdam Pharma Co NV's EV-to-EBIT falls into.


NewAmsterdam Pharma Co NV EV-to-EBIT Calculation

NewAmsterdam Pharma Co NV's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=1363.605/-176.91
=-7.71

NewAmsterdam Pharma Co NV's current Enterprise Value is $1,363.61 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NewAmsterdam Pharma Co NV's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-176.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NewAmsterdam Pharma Co NV  (NAS:NAMS) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

NewAmsterdam Pharma Co NV's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-176.91/580.797666
=-30.46 %

NewAmsterdam Pharma Co NV's Enterprise Value for the quarter that ended in Dec. 2023 was $580.80 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NewAmsterdam Pharma Co NV's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-176.91 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NewAmsterdam Pharma Co NV EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

NewAmsterdam Pharma Co NV (NewAmsterdam Pharma Co NV) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (NAS:NAMS) » Definitions » EV-to-EBIT
Comparable Companies
MDXG VERV AKRO ADMA ICPT SLNO INVA OLMA NVAX COGT OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
KH6:Germany
Address
Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
Website
https://www.newamsterdampharma.com
NewAmsterdam Pharma Co NV is a clinical-stage company focused on the research and development of transformative therapies for metabolic diseases and Alzheimer's disease.